Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Prospective, Randomized, Open-label, Blind Evaluator (PROBE) Study Evaluating the Efficacy and Safety of (LMW) Heparin/Edoxaban Versus Dalteparin in Venous Thromboembolism Associated With Cancer

NCT02073682 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT02073682
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02073682 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Prospective, Randomized, Open-label, Blind Evaluator (PROBE) Study Evaluating the Efficacy and Safety of (LMW) Heparin/Edoxaban Versus Dalteparin in Venous Thromboembolism Associated With Cancer
Lead sponsor
Daiichi Sankyo
Phase
Phase 3
Overall status
Completed
Start date
July 16, 2015
Completion date
September 15, 2017
Enrollment
1,046 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, deep vein thrombosis (dvt), pulmonary embolism (pe), venous thromboembolism (vte)